CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 71 enrolled
Drug / intervention
Panzyga +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04508530
NCT04508530Phase 3Completed
CompareCT.gov

A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Octapharma·interventional·Posted Aug 11, 2020·Updated Jan 7, 2026

In Brief

A Phase 3 clinical trial evaluating Panzyga and Placebo for Pediatric Acute-Onset Neuropsychiatric Syndrome. Completed, enrolled 71 participants across 12 sites in 3 countries.

Detailed Summary

A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Acute-Onset Neuropsychiatric Syndrome
CountriesItaly, Sweden, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedAug 11, 2020
Enrollment StartJun 30, 2021
Primary CompletionAug 27, 2024
Study CompletionOct 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.9 years ago

Interventions

Panzygabiological

Panzyga 10% IVIG

Placeboother

Placebo